Tag:
QVA149
Latest Headlines
Latest Headlines
Novartis touts positive results for COPD inhalant
Novartis is reporting positive results from Phase III trials of QVA149, a COPD drug that uses the company's Breezhaler dry powder inhaler for delivery
Novartis posts promising Phase III results for blockbuster hopeful QVA149
Novartis touted a slate of positive results for its COPD blockbuster hopeful QVA149, heralding promising results from three Phase III studies.
Forest Labs notches victory en route to FDA ruling on COPD drug
Eyeing the major market for a chronic lung condition, Forest Laboratories ( $FRX ) picked up the backing of an FDA panel for its experimental COPD drug known as aclidinium. It's a key endorsement...
PhRMA's COPD pipeline report spotlights blockbuster hopefuls
Anyone looking for a basic primer on experimental COPD drugs should check out PhRMA's latest compilation of new drugs in the pipeline. The big trade group found 54 COPD studies underway, which
Novartis signals serious U.S. delay for blockbuster COPD program
Novartis's blockbuster plans to develop a game-changing combo COPD therapy for the U.S. market have run into a serious delay. The pharma giant noted today that investigators will need to come up with
Novartis unveils more promising Ph3 data on COPD program
Novartis continues to rack up an impressive set of late-stage data on NVA237, an experimental COPD treatment that is considered a likely winner at the FDA. The data demonstrated the treatment was
FDA experts turn thumbs down on Novartis's high-dose COPD drug
An FDA advisory committee has given Novartis ( $NVS ) a key endorsement for a low-dose version of its inhaled COPD treatment indacaterol. But analysts fretted over the blockbuster implications of the
